Nuvation Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Nuvation Bio
NUVB Stock  USD 5.71  0.07  1.24%   
Nuvation Bio's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Nuvation Bio's valuation are provided below:
Gross Profit
14.5 M
Market Capitalization
1.9 B
Enterprise Value Revenue
54.6827
Revenue
26.7 M
Earnings Share
(0.49)
We have found one hundred twenty available fundamental ratios for Nuvation Bio, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of Nuvation Bio last-minute market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road.

Nuvation Bio Total Revenue

9.51 Million

Check Nuvation Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nuvation Bio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 645.4 K, Interest Expense of 372.5 K or Selling General Administrative of 80.6 M, as well as many indicators such as Price To Sales Ratio of 72.65, Dividend Yield of 0.0 or PTB Ratio of 1.46. Nuvation financial statements analysis is a perfect complement when working with Nuvation Bio Valuation or Volatility modules.
  
Build AI portfolio with Nuvation Stock
Check out the analysis of Nuvation Bio Correlation against competitors.
For information on how to trade Nuvation Stock refer to our How to Trade Nuvation Stock guide.

Nuvation Bio Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets464.1 M621.7 M237.7 M
Slightly volatile
Short and Long Term Debt Total10.8 M10.3 M3.1 M
Slightly volatile
Other Current Liabilities38.8 M37 M8.6 M
Slightly volatile
Total Current Liabilities70.3 M67 M15.1 M
Slightly volatile
Accounts Payable7.7 M7.3 M2 M
Slightly volatile
Cash54.3 M41.1 M26 M
Slightly volatile
Cash And Short Term Investments451.8 M578.1 M229.8 M
Slightly volatile
Common Stock Shares Outstanding237.3 M309.1 M207.4 M
Slightly volatile
Liabilities And Stockholders Equity464.1 M621.7 M237.7 M
Slightly volatile
Other Current Assets8.8 M8.4 M2.3 M
Slightly volatile
Total Liabilities92.8 M88.4 M20 M
Slightly volatile
Total Current Assets459.3 M605.2 M234.6 M
Slightly volatile
Short Term Debt9.6 M9.1 M2.2 M
Slightly volatile
Property Plant And Equipment Net3.1 M3.4 M1.7 M
Slightly volatile
Non Current Assets Total17.4 M16.5 M4.4 M
Slightly volatile
Non Currrent Assets Other8.2 M7.8 M1.7 M
Slightly volatile
Net Receivables19.7 M18.7 M4.3 M
Slightly volatile
Short Term Investments463.8 M537 M268.8 M
Slightly volatile
Common Stock817.4 M1.6 B408.5 M
Slightly volatile
Property Plant Equipment1.6 M1 M949 K
Slightly volatile
Other Liabilities928.6 K977.5 K1 M
Pretty Stable
Warrants91.4 M102.9 M112.3 M
Slightly volatile
Common Stock Total Equity724.1 M1.1 B411.3 M
Slightly volatile
Non Current Liabilities Total22.5 M21.4 M4.9 M
Slightly volatile
Capital Surpluse18.6 M20.9 M22.8 M
Slightly volatile
Inventory776.5 M739.5 M242.4 M
Slightly volatile
Net Invested Capital576.1 M540.6 M303.4 M
Slightly volatile
Property Plant And Equipment Gross4 M4.4 M2 M
Slightly volatile
Capital Stock978.7 M1.6 B582.5 M
Slightly volatile
Non Current Liabilities Other3.3 M3.5 M16.7 M
Slightly volatile
Current Deferred Revenue8.9 M10 M10.9 M
Slightly volatile
Short and Long Term Debt5 M5.7 M6.2 M
Slightly volatile
Intangible Assets3.7 M4.2 M4.5 M
Slightly volatile

Nuvation Bio Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization645.4 K614.7 K681.9 K
Slightly volatile
Selling General Administrative80.6 M76.7 M19.5 M
Slightly volatile
Other Operating Expenses725.1 M690.6 M142 M
Slightly volatile
Research Development633 M602.8 M120.6 M
Slightly volatile
Total Operating Expenses716.6 M682.4 M140.6 M
Slightly volatile
Selling And Marketing Expenses1.4 M2.9 M912.1 K
Slightly volatile
Net Interest Income32.3 M30.7 M8.6 M
Slightly volatile
Interest Income32.7 M31.1 M8.8 M
Slightly volatile
Cost Of Revenue8.5 M8.1 M1.5 M
Slightly volatile
Reconciled Depreciation824.7 K785.5 K237.1 K
Slightly volatile
Non Operating Income Net Other12.2 M17.9 M9.2 M
Slightly volatile

Nuvation Bio Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation824.7 K785.5 K184.2 K
Slightly volatile
Capital Expenditures268.1 K145.8 K472.5 K
Slightly volatile
Total Cash From Financing Activities283 K297.9 K53.7 M
Pretty Stable
End Period Cash Flow54.3 M41.1 M26 M
Slightly volatile
Change To Netincome8.6 M8.5 M7.8 M
Pretty Stable
Begin Period Cash Flow56.7 M49 M24.5 M
Slightly volatile
Sale Purchase Of Stock802.8 K845.1 K88.1 M
Slightly volatile
Stock Based Compensation39 M37.1 M10.5 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio72.6581.7389.2061
Slightly volatile
Days Sales Outstanding604680742
Slightly volatile
Stock Based Compensation To Revenue3.283.694.0272
Slightly volatile
Capex To Depreciation0.260.2730.1647
Slightly volatile
EV To Sales69.9278.6685.8605
Slightly volatile
Payables Turnover1.051.00.4136
Slightly volatile
Sales General And Administrative To Revenue6.787.638.3266
Slightly volatile
Research And Ddevelopement To Revenue53.2659.9265.4052
Slightly volatile
Capex To Revenue0.01650.01850.0202
Slightly volatile
Cash Per Share1.51.680.9608
Slightly volatile
Days Payables Outstanding3583765.1 K
Slightly volatile
Income Quality0.250.260.6199
Pretty Stable
Intangibles To Total Assets0.00680.00770.0084
Slightly volatile
Net Debt To EBITDA0.05170.05440.2742
Slightly volatile
Current Ratio7.738.1314.0006
Slightly volatile
Receivables Turnover0.380.430.474
Slightly volatile
Capex Per Share7.0E-47.0E-40.0022
Slightly volatile
Revenue Per Share0.02340.02640.0288
Slightly volatile
Interest Debt Per Share0.03250.0310.0124
Slightly volatile
Debt To Assets0.0180.0192.015
Slightly volatile
Operating Cycle604680742
Slightly volatile
Days Of Payables Outstanding3583765.1 K
Slightly volatile
Ebt Per Ebit1.011.11.0022
Slightly volatile
Quick Ratio7.738.1314.0006
Slightly volatile
Cash Ratio0.520.551.6025
Slightly volatile
Days Of Sales Outstanding604680742
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.151.032
Slightly volatile
Fixed Asset Turnover2.12.372.5878
Slightly volatile
Debt Ratio0.0180.0192.015
Slightly volatile
Price Sales Ratio72.6581.7389.2061
Slightly volatile
Asset Turnover0.01170.01310.0143
Slightly volatile
Gross Profit Margin0.080.09090.0992
Slightly volatile

Nuvation Bio Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2 B2.3 B2.5 B
Slightly volatile
Enterprise Value2 B2.3 B2.5 B
Slightly volatile

Nuvation Fundamental Market Drivers

Nuvation Upcoming Events

20th of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Nuvation Bio Financial Statements

Nuvation Bio stakeholders use historical fundamental indicators, such as Nuvation Bio's revenue or net income, to determine how well the company is positioned to perform in the future. Although Nuvation Bio investors may analyze each financial statement separately, they are all interrelated. For example, changes in Nuvation Bio's assets and liabilities are reflected in the revenues and expenses on Nuvation Bio's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Nuvation Bio. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue10 M8.9 M
Total Revenue9.1 M9.5 M
Cost Of Revenue8.1 M8.5 M
Stock Based Compensation To Revenue 3.69  3.28 
Sales General And Administrative To Revenue 7.63  6.78 
Research And Ddevelopement To Revenue 59.92  53.26 
Capex To Revenue 0.02  0.02 
Revenue Per Share 0.03  0.02 
Ebit Per Revenue(67.75)(71.13)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
When determining whether Nuvation Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Nuvation Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nuvation Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nuvation Bio Stock:
How To Invest In Nuvation
Details
Is Nuvation Stock a good investment?
Details
What is Nuvation Bio's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Nuvation Bio Correlation against competitors.
For information on how to trade Nuvation Stock refer to our How to Trade Nuvation Stock guide.
You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nuvation Bio. Anticipated expansion of Nuvation directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Nuvation Bio assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(0.49)
Revenue Per Share
0.079
Quarterly Revenue Growth
17.047
Return On Assets
(0.25)
Return On Equity
(0.52)
Understanding Nuvation Bio requires distinguishing between market price and book value, where the latter reflects Nuvation's accounting equity. The concept of intrinsic value - what Nuvation Bio's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Nuvation Bio's price substantially above or below its fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between Nuvation Bio's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Nuvation Bio should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Nuvation Bio's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY